Objective: To evaluate the efficacy and safety of cetuximab combined with chemotherapy in colorectal cancer (CRC). Methods: 35 cases of CRC were retrospectively analyzed. Efficacy and adverse events were observed. Results: 29 cases of CRC were evaluated by RECIST criteria, showing 7 PR (partial response, 24.1%) and 15 SD (stable disease, 51.8%), disease control rate (DC) was 75.9%. Subgroup analysis showed response rate (RR) of 36.4% and DC of 91% in the 1st line therapy, RR of 20% and DC of 70% in the 2nd line therapy, RR of 12.5% and DC of 62.5% in heavily pretreated cases. Rash appeared in 74.3% of patients (grade 3 was 8.6%), and the severity was relevant with disease control rate (DC). Neutropenia of grade 3/4 was 14.3%, and infusion related reaction (IRR) of grade 3 happened in 1 case (2.9%). Conclusion: Cetuximab combined with chemotherapy is safe and effective for patients with metastatic colorectal cancer. The combination therapy shows high DC, especially in 1st line therapy. Severity of rash may predict efficacy. Results: 29 cases of CRC were evaluated by RECIST criteria, showing The subgroup analysis showed a response rate (RR) of 36.4% and DC of 91% in the 1st line (75.1%), with a partial response of 24.1% and 15 SD (stable disease, 51.8% RR of 20% and DC of 70% in the 2nd line therapy, RR of 12.5% ​​and DC of 62.5% in heavily pretreated cases. Rash was 74.3% of patients (grade 3 was 8.6%), and the severity was relevant with disease control rate (DC). Neutropenia of grade 3/4 was 14.3%, and infusion related reaction (IRR) of grade 3 happened in 1 case (2.9%). Conclusion: Cetuximab combined with chemotherapy is safe and effective for patients with metastatic colorectal cancer. The combination therapy shows high DC, especially in 1st line therapy. Severity of rash may predict efficacy.